Simple item page
 

Daily Treatment of Mice with Type 2 Diabetes with Adropin for Four Weeks Improves Glucolipid Profile, Reduces Hepatic Lipid Content and Restores Elevated Hepatic Enzymes in Serum

cris.virtual.author-orcid0000-0003-4059-1362
cris.virtual.author-orcid0000-0003-0715-0223
cris.virtual.author-orcid0000-0002-7182-6905
cris.virtual.author-orcid0000-0002-3651-0972
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid0000-0003-0617-1233
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid0000-0002-1948-6544
cris.virtualsource.author-orcid9118c61a-b066-4efc-a7af-486f9ebf9021
cris.virtualsource.author-orcid0c22ceb5-e5c6-4f5d-a0fd-8ec91a16efa9
cris.virtualsource.author-orcid325904ea-6775-4d8a-b846-0104d9ec20ca
cris.virtualsource.author-orcid652e209d-434a-47b3-b5fb-64c0aac5a84c
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid0be4a127-7f45-4d60-8bef-6d03866be0e6
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcidb5ca3f7e-8c5b-47d7-b9c2-582f5ffa0e29
dc.abstract.enAdropin is a peptide hormone encoded by Energy Homeostasis Associated gene. Adropin modulates energy homeostasis and metabolism of lipids and carbohydrates. There is growing evidence demonstrating that adropin enhances insulin sensitivity and lowers hyperlipidemia in obese mice. The aim of this study was to investigate the effects of daily administration of adropin for four weeks in mice with experimentally induced type 2 diabetes (T2D). Adropin improved glucose control without modulating insulin sensitivity. Adropin reduced body weight, size of adipocytes, blood levels of triacylglycerol and cholesterol in T2D mice. T2D mice treated with adropin had lower liver mass, reduced hepatic content of triacylglycerol and cholesterol. Furthermore, adropin attenuated elevated blood levels of hepatic enzymes (ALT, AST, GGT and ALP) in T2D mice. In T2D mice, adropin increased the circulating adiponectin level. Adropin had no effects on circulating insulin and glucagon levels and did not alter pancreatic islets morphology. These results suggest that adropin improves glucose control, lipid metabolism and liver functions in T2D. In conjunction with reduced lipid content in hepatocytes, these results render adropin as an interesting candidate in therapy of T2D.
dc.affiliationWydział Medycyny Weterynaryjnej i Nauk o Zwierzętach
dc.affiliation.instituteKatedra Fizjologii, Biochemii i Biostruktury Zwierząt
dc.affiliation.instituteKatedra Nauk Przedklinicznych i Chorób Zakaźnych
dc.contributor.authorSkrzypski, Marek
dc.contributor.authorKołodziejski, Paweł
dc.contributor.authorPruszyńska-Oszmałek, Ewa
dc.contributor.authorWojciechowicz, Tatiana
dc.contributor.authorJanicka, Paulina
dc.contributor.authorKrążek, Małgorzata
dc.contributor.authorMałek, Emilian
dc.contributor.authorStrowski, Mathias Z.
dc.contributor.authorNowak, Krzysztof W.
dc.date.access2026-02-27
dc.date.accessioned2026-02-27T06:35:13Z
dc.date.available2026-02-27T06:35:13Z
dc.date.copyright2022-08-29
dc.date.issued2022
dc.description.abstract<jats:p>Adropin is a peptide hormone encoded by Energy Homeostasis Associated gene. Adropin modulates energy homeostasis and metabolism of lipids and carbohydrates. There is growing evidence demonstrating that adropin enhances insulin sensitivity and lowers hyperlipidemia in obese mice. The aim of this study was to investigate the effects of daily administration of adropin for four weeks in mice with experimentally induced type 2 diabetes (T2D). Adropin improved glucose control without modulating insulin sensitivity. Adropin reduced body weight, size of adipocytes, blood levels of triacylglycerol and cholesterol in T2D mice. T2D mice treated with adropin had lower liver mass, reduced hepatic content of triacylglycerol and cholesterol. Furthermore, adropin attenuated elevated blood levels of hepatic enzymes (ALT, AST, GGT and ALP) in T2D mice. In T2D mice, adropin increased the circulating adiponectin level. Adropin had no effects on circulating insulin and glucagon levels and did not alter pancreatic islets morphology. These results suggest that adropin improves glucose control, lipid metabolism and liver functions in T2D. In conjunction with reduced lipid content in hepatocytes, these results render adropin as an interesting candidate in therapy of T2D.</jats:p>
dc.description.accesstimeat_publication
dc.description.bibliographyil., bibliogr.
dc.description.financepublication_nocost
dc.description.financecost0,00
dc.description.if5,6
dc.description.number17
dc.description.points140
dc.description.versionfinal_published
dc.description.volume23
dc.identifier.doi10.3390/ijms23179807
dc.identifier.eissn1422-0067
dc.identifier.issn1661-6596
dc.identifier.urihttps://sciencerep.up.poznan.pl/handle/item/7516
dc.identifier.weblinkhttps://www.mdpi.com/1422-0067/23/17/9807
dc.languageen
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.relation.pagesart. 9807
dc.rightsCC-BY
dc.sciencecloudnosend
dc.share.typeOPEN_JOURNAL
dc.subject.enadipocytes
dc.subject.enadropin
dc.subject.enpancreatic islets
dc.subject.enmetabolism
dc.subject.entype 2 diabetes mellitus
dc.titleDaily Treatment of Mice with Type 2 Diabetes with Adropin for Four Weeks Improves Glucolipid Profile, Reduces Hepatic Lipid Content and Restores Elevated Hepatic Enzymes in Serum
dc.typeJournalArticle
dspace.entity.typePublication
oaire.citation.issue17
oaire.citation.volume23